Your browser is no longer supported. Please, upgrade your browser.
Settings
RAIN [NASD]
Rain Therapeutics Inc.
Index- P/E- EPS (ttm)- Insider Own19.47% Shs Outstand18.24M Perf Week12.34%
Market Cap335.46M Forward P/E- EPS next Y- Insider Trans- Shs Float1.93M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range14.31 - 23.90 Perf YTD16.39%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-23.05% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low28.56% ATR1.89
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility7.45% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.21 Prev Close16.67
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume668.73K Price18.39
Recom- SMA2012.86% SMA5012.86% SMA20012.86% Volume139,533 Change10.32%
May-07-21 07:54PM  
Apr-23-21 12:07PM  
Apr-22-21 07:03PM  
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 27Buy17.00550,0009,350,0002,537,019Apr 27 07:30 PM
Cormorant Asset Management, LPFormer 10% OwnerApr 27Buy17.00450,0007,650,0002,776,657Apr 29 04:02 PM
Davis Aaron I.DirectorApr 27Buy17.001,025,00017,425,0001,175,000Apr 27 05:09 PM
Boxer Capital, LLCDirectorApr 27Buy17.001,025,00017,425,0001,175,000Apr 27 05:11 PM
Boxer Capital, LLCDirectorApr 23Buy16.16150,0002,423,250150,000Apr 27 05:11 PM
Davis Aaron I.DirectorApr 23Buy16.16150,0002,423,250150,000Apr 27 05:09 PM
BERGER FRANKLIN MDirectorApr 23Buy16.95125,0002,118,900125,000Apr 27 05:05 PM